EPS8L3 Antibody

What is EPS8L3 and what is its role in cellular signaling?

EPS8L3 (Epidermal growth factor receptor pathway substrate 8-like protein 3) belongs to the EPS8 family of proteins that are involved in growth factor-stimulated signaling pathways. It is related to epidermal growth factor receptor pathway substrate 8 (EPS8), which is a substrate for the epidermal growth factor receptor (EGFR). While initially the function of EPS8L3 was poorly understood, recent research has identified its involvement in EGFR signaling pathways .

Unlike other members of the EPS8 family (EPS8, EPS8L1, and EPS8L2), EPS8L3 has unique functional characteristics. While it shares the ability to interact with Abi1 and Sos-1, EPS8L3 does not activate the Rac-GEF activity of Sos-1 and does not bind to actin in vivo, distinguishing it functionally from the other family members .

How does EPS8L3 differ structurally and functionally from other EPS8 family members?

The EPS8 family consists of EPS8 and three related proteins: EPS8L1, EPS8L2, and EPS8L3. These proteins share a collinear topology and display 27-42% identity to EPS8. The modular organization consists of three domains:

• An N-terminal region (37-52% identity with EPS8), with a predicted fold resembling a phosphotyrosine binding domain (PTB)

• A central SH3 domain (51-60% identity with EPS8)

• A C-terminal region (37-47% identity with EPS8) similar to the "effector region" of EPS8

Functionally, while EPS8L1 and EPS8L2 share critical biochemical properties with EPS8, including the ability to activate the Rac-GEF activity of Sos-1 and bind to actin in vivo, EPS8L3 lacks these capabilities. The C-terminal fragments of EPS8, EPS8L1, and EPS8L2 can associate with Sos-1 in vitro, but the C-terminal fragment of EPS8L3 does not show this association .

What evidence suggests EPS8L3 has a role in hepatocellular carcinoma (HCC)?

Recent studies have established EPS8L3 as a significant player in hepatocellular carcinoma (HCC). Research has revealed that:

These findings suggest that EPS8L3 plays a pivotal role in the tumorigenesis and progression of HCC, positioning it as a potential therapeutic target .

What mechanistic pathways explain EPS8L3's role in cancer progression?

EPS8L3 influences cancer progression through several mechanistic pathways:

• EGFR-ERK pathway modulation: EPS8L3 affects the activation of the EGFR-ERK pathway by modulating EGFR dimerization and internalization. This modulation may not depend on the formation of EPS8L3-SOS1-ABI1 complex, suggesting a distinct mechanism from other EPS8 family members .

• Cell cycle regulation: EPS8L3 knockdown experiments show an obvious increase of cells in G0/G1 phase and a significant reduction of cells in G2/M phase, indicating its role in cell cycle progression through downregulation of p21/p27 expression .

• Metastasis promotion: EPS8L3 upregulates matrix metalloproteinase-2 expression, which enhances migratory and invasive abilities of cancer cells .

These findings suggest that EPS8L3 operates through multiple signaling pathways to promote tumorigenesis and cancer progression.

What are the optimal protocols for using EPS8L3 antibodies in different experimental techniques?

For optimal results when working with EPS8L3 antibodies:

• Perform proper controls including positive and negative tissues

• Use appropriate antigen retrieval methods for fixed tissues

• Validate antibody specificity through knockdown/knockout models

• Optimize conditions for each specific application and sample type

• Store antibodies at -20°C in buffered solution containing glycerol to maintain stability

How can researchers validate the specificity of EPS8L3 antibodies for their experimental system?

Validation of EPS8L3 antibody specificity is critical for obtaining reliable experimental results. Multiple approaches should be employed:

• Genetic manipulation: Utilize siRNA or shRNA to knockdown EPS8L3 expression. For example, applying siRNAs targeted to EPS8L3 mRNA should result in reduced signal in antibody-based detection methods if the antibody is specific .

• Comparison across species: Test reactivity with human, mouse, and other species as appropriate for your model system. Note that some antibodies are specifically reactive to human EPS8L3, while others also detect mouse and monkey orthologs .

• Peptide competition assays: Pre-incubate the antibody with the immunizing peptide before application to samples. Specific binding should be blocked by the peptide.

• Multiple antibody comparison: Use antibodies raised against different epitopes of EPS8L3 to confirm staining patterns.

• Positive control tissues: Based on expression data, liver cancer tissues show high expression of EPS8L3 and can serve as positive controls for antibody validation .

• Cross-reactivity assessment: Test for potential cross-reactivity with other EPS8 family members (EPS8, EPS8L1, EPS8L2) given their sequence similarities (27-42% identity) .

How can EPS8L3 antibodies be used to investigate its role in EGFR signaling pathways?

To investigate EPS8L3's role in EGFR signaling pathways, researchers can employ several sophisticated approaches using EPS8L3 antibodies:

• Co-immunoprecipitation (Co-IP) studies: Use EPS8L3 antibodies to pull down protein complexes to identify binding partners within the EGFR signaling pathway. This approach has revealed that while EPS8L3 interacts with Abi1 and Sos-1 like other family members, it does not activate the Rac-GEF activity of Sos-1 .

• Proximity ligation assays (PLA): Combine EPS8L3 antibodies with antibodies against EGFR or downstream signaling components to visualize protein-protein interactions at endogenous levels.

• Phosphorylation dynamics: Use phospho-specific antibodies alongside total EPS8L3 antibodies to monitor how growth factor stimulation affects EPS8L3 phosphorylation status and correlate with EGFR pathway activation.

• Subcellular localization studies: Employ immunofluorescence with EPS8L3 antibodies to track changes in localization following EGFR activation. Unlike EPS8L1 and EPS8L2, EPS8L3 does not localize to PDGF-induced, F-actin-rich ruffles .

• Receptor internalization assays: Use EPS8L3 antibodies in conjunction with EGFR antibodies to visualize how EPS8L3 affects EGFR dimerization and internalization, which has been identified as one of its key mechanisms of action .

What strategies can resolve contradictory findings about EPS8L3 function across different cancer types?

Research has revealed potentially contradictory findings regarding EPS8L3's function across different cancer types. To resolve these contradictions, researchers should consider the following approaches:

• Cell-type specific analysis: Simultaneously examine multiple cancer cell lines with varied EPS8L3 expression levels using well-validated antibodies to determine if effects are cell-type dependent.

• Context-dependent signaling evaluation: Use antibody-based techniques (western blot, IHC, etc.) to examine the relationship between EPS8L3 expression and pathway activation markers across different tumor types. This may reveal context-dependent roles.

• Mutation and isoform mapping: Employ antibodies recognizing different epitopes to investigate whether different isoforms or post-translationally modified versions of EPS8L3 exist in different cancer types, potentially explaining functional differences.

• Multi-omics correlation: Correlate protein-level findings (using antibodies) with transcriptomic and genomic data to identify potential genetic alterations that modify EPS8L3 function.

• Functional domain mapping: Use domain-specific antibodies to investigate whether specific domains of EPS8L3 are required for different functions in different cancer contexts.

How can researchers design experiments to explore EPS8L3's potential as a therapeutic target?

Based on findings that EPS8L3a plays a pivotal role in tumorigenesis and HCC progression , researchers can design experiments to explore its therapeutic potential:

• Target validation studies:

  • Use antibodies to confirm EPS8L3 overexpression in patient-derived samples

  • Correlate expression levels with clinical outcomes

  • Perform knockout/knockdown studies combined with antibody detection to measure effects on tumorigenicity

• Drug discovery approaches:

  • Develop high-throughput screening assays using EPS8L3 antibodies to identify compounds that reduce expression or disrupt key interactions

  • Use proximity-based assays with EPS8L3 antibodies to identify molecules that interfere with protein-protein interactions

• Biomarker development:

  • Validate EPS8L3 antibodies for diagnostic applications in tissue samples

  • Develop quantitative assays to measure EPS8L3 levels as potential predictive biomarkers

• Combination therapy assessment:

  • Use antibodies to monitor changes in EPS8L3 expression or localization when combined with current standard therapies

  • Identify synergistic approaches that counteract EPS8L3-mediated treatment resistance

• In vivo model evaluation:

  • Develop mouse models with manipulated EPS8L3 expression

  • Use antibodies for pharmacodynamic studies to confirm target engagement of therapeutic compounds

What are the critical considerations for optimizing western blot protocols for EPS8L3 detection?

For optimal western blot detection of EPS8L3 (molecular weight approximately 67 kDa) , researchers should consider:

• Sample preparation:

  • Use appropriate lysis buffers containing protease inhibitors to prevent degradation

  • Include phosphatase inhibitors if investigating phosphorylation status

  • Denature samples at appropriate temperature (typically 95°C for 5 minutes)

• Gel selection and electrophoresis:

  • Use 8-10% polyacrylamide gels for optimal resolution around 67 kDa

  • Include positive control samples (e.g., liver cancer cell lines known to express EPS8L3)

  • Use pre-stained molecular weight markers to confirm target band size

• Transfer and blocking:

  • Optimize transfer conditions for proteins in the 60-70 kDa range

  • Use PVDF membranes for better protein retention

  • Block with 5% non-fat dry milk or BSA in TBST to reduce background

• Antibody incubation:

  • Use recommended dilution (typically 1:1000)

  • Incubate overnight at 4°C for primary antibody

  • Wash thoroughly to reduce background

  • Use appropriate HRP-conjugated secondary antibody

• Detection and analysis:

  • Use enhanced chemiluminescence (ECL) detection systems

  • Optimize exposure time to prevent saturation

  • Include loading controls (e.g., GAPDH, β-actin) for normalization

  • Quantify band intensity using appropriate software

What immunohistochemistry approaches best reveal EPS8L3's tissue distribution and subcellular localization?

For optimal immunohistochemical detection of EPS8L3:

• Tissue preparation:

  • For formalin-fixed paraffin-embedded (FFPE) tissues, use appropriate antigen retrieval methods (typically heat-induced epitope retrieval in citrate buffer pH 6.0 or EDTA buffer pH 9.0)

  • For frozen sections, optimize fixation (4% paraformaldehyde) and permeabilization conditions

• Antibody selection and optimization:

  • Use recommended dilutions (1:50-1:200 for IHC)

  • Test multiple antibodies recognizing different epitopes if possible

  • Include positive control tissues (liver cancer tissues show high expression)

  • Include negative controls (omit primary antibody or use isotype control)

• Signal detection systems:

  • Use sensitive detection systems like polymer-based HRP detection

  • For co-localization studies, employ fluorescent secondary antibodies and counterstain with DAPI for nuclear visualization

• Analysis approaches:

  • Score staining intensity using established systems (0, 1+, 2+, 3+)

  • Quantify percentage of positive cells in different tissue compartments

  • Use digital pathology platforms for automated quantification

  • For subcellular localization, use high-magnification imaging to distinguish membrane, cytoplasmic, and nuclear staining patterns

• Multi-labeling strategies:

  • Combine EPS8L3 antibodies with markers for specific cell types to identify expressing populations

  • Use dual immunofluorescence with EGFR or other signaling pathway components to assess co-localization

How should researchers design experiments to investigate EPS8L3's role in diverse signaling networks?

To comprehensively investigate EPS8L3's role in signaling networks, researchers should design multifaceted experimental approaches:

• Genetic manipulation strategies:

  • Design siRNAs targeting specific regions of EPS8L3 mRNA (see previous successful sequences used in published studies)

  • Develop stable knockdown cell lines using shRNA (target sequences available from published studies)

  • Generate knockout cell lines using CRISPR-Cas9

  • Create overexpression systems with tagged versions (FLAG, GFP, etc.) for visualization and pulldown experiments

• Pathway activation analysis:

  • Stimulate cells with growth factors (EGF, PDGF) after EPS8L3 manipulation

  • Use phospho-specific antibodies to analyze activation of EGFR-ERK pathway components

  • Measure changes in Rac-GEF activity using pull-down assays

  • Compare results to other EPS8 family members to identify unique functions

• Protein-protein interaction studies:

  • Perform co-immunoprecipitation with antibodies against EPS8L3 followed by mass spectrometry to identify novel binding partners

  • Use proximity ligation assays to confirm interactions in intact cells

  • Compare interactome between different cell types to identify context-specific partners

• Domain-function relationship analysis:

  • Create deletion constructs of EPS8L3 to identify domains required for specific functions

  • Generate chimeric proteins between EPS8L3 and other family members to identify functional domains

• Downstream effect measurement:

  • Monitor changes in gene expression using RNA-seq after EPS8L3 manipulation

  • Analyze cell cycle effects using flow cytometry

  • Measure cell migration, invasion, and proliferation in functional assays

What controls are essential when using EPS8L3 antibodies to avoid misinterpretation of results?

To ensure reliable interpretation of results when using EPS8L3 antibodies, the following controls are essential:

• Antibody validation controls:

  • Include EPS8L3 knockdown/knockout samples to confirm antibody specificity

  • Use multiple antibodies targeting different epitopes of EPS8L3 when possible

  • Include positive control samples known to express EPS8L3 (e.g., liver cancer cell lines)

  • Perform peptide competition assays to confirm specificity

• Experimental design controls:

  • Use both gain-of-function (overexpression) and loss-of-function (knockdown) approaches in parallel

  • Include proper negative controls (empty vector, non-targeting siRNA)

  • Perform rescue experiments by re-expressing EPS8L3 in knockdown/knockout conditions

• Cross-reactivity controls:

  • Test for potential cross-reactivity with other EPS8 family members

  • Include samples with manipulated levels of EPS8, EPS8L1, and EPS8L2 to assess potential antibody cross-reactivity

  • Consider the structural similarities between family members when interpreting results

• Technical controls:

  • Include loading controls for western blots (β-actin, GAPDH)

  • Use isotype controls for immunoprecipitation experiments

  • Include background staining controls in immunohistochemistry/immunofluorescence (secondary antibody only)

  • Validate quantification methods using standard curves where applicable

• Biological replicates and statistical analysis:

  • Perform experiments with sufficient biological replicates (minimum n=3)

  • Apply appropriate statistical tests based on data distribution

  • Report effect sizes alongside p-values

By incorporating these comprehensive controls, researchers can minimize misinterpretation of results and enhance the reproducibility and reliability of their findings related to EPS8L3 function.

What emerging technologies might enhance detection and functional analysis of EPS8L3?

Several cutting-edge technologies offer promising approaches for advancing EPS8L3 research:

• Advanced imaging techniques:

  • Super-resolution microscopy (STORM, PALM, STED) to visualize EPS8L3 localization at nanoscale resolution

  • Live-cell imaging with tagged EPS8L3 to track dynamics during signaling events

  • Lattice light-sheet microscopy for 3D visualization of EPS8L3 in living cells

  • Correlative light and electron microscopy (CLEM) to connect protein localization with ultrastructural features

• Proteomics and interactomics:

  • Proximity-dependent biotin identification (BioID or TurboID) fused to EPS8L3 to map protein interaction networks

  • Thermal proteome profiling to identify compounds that bind to and stabilize EPS8L3

  • Cross-linking mass spectrometry to identify direct binding interfaces

• Single-cell analysis techniques:

  • Single-cell proteomics to examine EPS8L3 expression heterogeneity in tumors

  • CITE-seq combining transcriptomics with antibody-based protein detection

  • Spatial transcriptomics coupled with protein detection to map EPS8L3 expression in tissue context

• Structural biology approaches:

  • Cryo-EM studies of EPS8L3 in complex with interacting partners

  • Hydrogen-deuterium exchange mass spectrometry to study conformational changes upon binding

  • AlphaFold or RoseTTAFold predictions validated with experimental approaches

• Genome engineering:

  • CRISPR activation/inhibition systems for precise modulation of EPS8L3 expression

  • Knock-in of endogenous tags for visualization and pulldown without overexpression artifacts

  • Base editing or prime editing to introduce specific mutations for structure-function studies

How can contradictory data about EPS8L3's role in different experimental systems be reconciled?

To reconcile contradictory findings about EPS8L3 across different experimental systems, researchers should implement systematic approaches:

• Standardized reporting and methodology:

  • Establish detailed protocols for EPS8L3 detection and functional studies

  • Report complete antibody information including catalog numbers, dilutions, and validation methods

  • Create community standards for EPS8L3 research similar to MIQE guidelines for qPCR

• Comparative analysis across systems:

  • Directly compare EPS8L3 function in multiple cell lines under identical experimental conditions

  • Analyze EPS8L3 isoform expression across different systems using isoform-specific detection methods

  • Create a central repository of EPS8L3 functional data across different experimental systems

• Context-dependent signaling analysis:

  • Map the signaling network architecture in different cell types to identify context-specific interactors

  • Analyze post-translational modifications of EPS8L3 across different systems

  • Test the hypothesis that EPS8L3 function depends on the relative expression of other signaling components

• Reconciliation through systems biology:

  • Develop computational models that can account for seemingly contradictory findings

  • Use network analysis to identify conditional dependencies that explain context-specific functions

  • Employ machine learning approaches to identify patterns in experimental data that predict when specific functions will be observed

• Meta-analysis approaches:

  • Conduct formal meta-analyses of published EPS8L3 findings with attention to methodological differences

  • Perform collaborative multi-laboratory studies using standardized reagents and protocols

  • Establish consensus guidelines for interpreting EPS8L3 function based on experimental context

By implementing these approaches, researchers can develop a more nuanced understanding of EPS8L3 biology that accommodates apparently contradictory findings within a coherent conceptual framework.